Residency · Residency · Internal Medicine
Rheumatoid Arthritis: Early Diagnosis and DMARD Therapy
Introduction
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by symmetric inflammatory polyarthritis that leads to progressive joint destruction if untreated. Early diagnosis and prompt initiation of disease-modifying antirheumatic drugs (DMARDs) fundamentally alter disease trajectory. The internist is often the first to encounter early RA and must recognize it, initiate appropriate workup, and facilitate timely rheumatology referral.
Epidemiology and Pathophysiology
- Prevalence approximately 0.5-1% worldwide; female-to-male ratio 2-3:1
- Peak onset in the fifth and sixth decades; can occur at any age
- Genetic predisposition: HLA-DRB1 shared epitope is the strongest genetic risk factor
- Environmental triggers: smoking is the most important modifiable risk factor (especially in seropositive disease)
- Pathology: synovial inflammation leads to pannus formation, cartilage destruction, and bone erosion
Clinical Presentation
Articular Features
- Symmetric inflammatory polyarthritis of small joints: MCPs, PIPs, wrists, MTPs
- Morning stiffness lasting > 30 minutes (often > 1 hour)
- DIP joints are typically spared (helps distinguish from osteoarthritis)
- Boggy synovitis on examination; tenderness on metacarpal squeeze test
- Late findings: ulnar deviation, swan-neck and boutonniere deformities, subluxation
Extra-Articular Manifestations
- Rheumatoid nodules: firm subcutaneous nodules over extensor surfaces; seropositive disease
- Pulmonary: interstitial lung disease (ILD), pleural effusions, rheumatoid nodules
- Ocular: scleritis, episcleritis, keratoconjunctivitis sicca (secondary Sjogren syndrome)
- Cardiovascular: accelerated atherosclerosis; pericarditis
- Hematologic: anemia of chronic disease, Felty syndrome (RA + splenomegaly + neutropenia)
- Cervical spine: atlantoaxial subluxation; evaluate before intubation in longstanding disease
Diagnosis
2010 ACR/EULAR Classification Criteria
| Domain | Criteria | Score |
|---|---|---|
| Joint involvement | 1 large joint | 0 |
| 2-10 large joints | 1 | |
| 1-3 small joints | 2 | |
| 4-10 small joints | 3 | |
| >10 joints (at least 1 small) | 5 | |
| Serology | Negative RF and anti-CCP | 0 |
| Low-positive RF or anti-CCP | 2 | |
| High-positive RF or anti-CCP (>3x ULN) | 3 | |
| Acute-phase reactants | Normal ESR and CRP | 0 |
| Abnormal ESR or CRP | 1 | |
| Duration | < 6 weeks | 0 |
| ≥ 6 weeks | 1 | |
| Score ≥ 6/10 = classifies as RA |
- Designed for early disease; score >= 6/10 classifies as RA
- Joint involvement: number and size of affected joints (small joints score higher)
- Serology: RF and anti-CCP (high-titer positive scores highest)
- Acute-phase reactants: elevated ESR or CRP
- Duration of symptoms: >= 6 weeks
Key Laboratory Tests
- Rheumatoid factor (RF): sensitivity ~70%; not specific (elevated in infections, liver disease, other autoimmune diseases)
- Anti-citrullinated peptide antibody (anti-CCP): sensitivity ~70%, specificity > 95%; can precede symptoms by years
- ESR and CRP: markers of inflammation; useful for monitoring disease activity
- CBC, CMP, hepatitis B and C serologies (baseline before DMARD initiation)
Imaging
- X-rays of hands and feet: baseline; look for periarticular osteopenia, joint space narrowing, erosions
- Ultrasound: detects subclinical synovitis and early erosions; increasingly used in clinic
- MRI: most sensitive for early bone edema and erosions; not routinely needed
Treatment
Guiding Principles
- Treat-to-target strategy: aim for clinical remission or low disease activity
- Early aggressive therapy prevents irreversible joint damage; the "window of opportunity"
- Reassess disease activity every 3 months and adjust therapy if target not met
- Use validated disease activity scores: DAS28, CDAI, SDAI
Conventional Synthetic DMARDs (csDMARDs)
- Methotrexate: first-line DMARD; start 15 mg weekly, titrate to 25 mg weekly
- Supplement with folic acid 1 mg daily to reduce side effects
- Monitor CBC, LFTs, creatinine every 3 months
- Contraindicated in pregnancy (teratogenic); ensure reliable contraception
- Screen for hepatitis B/C and check baseline chest X-ray
- Leflunomide: alternative to methotrexate; 20 mg daily
- Sulfasalazine: add-on or monotherapy; well tolerated
- Hydroxychloroquine: mild disease or combination therapy; annual eye exam required
Biologic DMARDs (bDMARDs)
- Added when csDMARDs fail to achieve target; typically combined with methotrexate
- TNF inhibitors: etanercept, adalimumab, infliximab, certolizumab, golimumab
- IL-6 receptor inhibitor: tocilizumab, sarilumab
- T-cell costimulation inhibitor: abatacept
- B-cell depleting: rituximab (typically after TNF inhibitor failure)
- Screen for latent tuberculosis (IGRA) and hepatitis B before starting biologics
Targeted Synthetic DMARDs (tsDMARDs)
- JAK inhibitors: tofacitinib, baricitinib, upadacitinib
- Oral agents; effective after csDMARD failure
- Increased risk of VTE, major cardiovascular events, and malignancy in some populations (ORAL Surveillance trial)
- Currently recommended preferentially in patients without cardiovascular risk factors
Corticosteroids
- Bridge therapy during DMARD initiation: low-dose prednisone (<=10 mg/day)
- Taper and discontinue as DMARDs take effect (typically 4-8 weeks)
- Intra-articular injections for mono- or oligoarticular flares
- Chronic corticosteroid use should be avoided; associated with infections, osteoporosis, and metabolic complications
Monitoring and Preventive Care
- Disease activity assessment every 3 months until target reached, then every 6 months
- Annual chest X-ray consideration for ILD screening in high-risk patients
- Pneumococcal and influenza vaccination before immunosuppression when possible
- Bone density screening with chronic corticosteroid use
- Cardiovascular risk assessment: RA itself is an independent cardiovascular risk factor
Key Clinical Pearls
- Anti-CCP is the most specific serologic test for RA and can be positive years before symptom onset
- Start methotrexate early; delayed DMARD initiation leads to irreversible erosive damage
- Always supplement methotrexate with folic acid and screen for hepatitis B/C and tuberculosis
- Morning stiffness > 30 minutes with symmetric small-joint swelling strongly suggests inflammatory arthritis
- RA patients have increased cardiovascular risk; manage traditional risk factors aggressively
References
- Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an ACR/EULAR collaborative initiative. Arthritis Rheum. 2010;62(9):2569-2581.
- Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924-939.
- Smolen JS, Landewe RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3-18.
- Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis (ORAL Surveillance). N Engl J Med. 2022;386(4):316-326.